Moderna will show early results from its mRNA-2808 trial at the 2026 ASH Annual Meeting.

MRNA · Moderna, Inc.

The AI's read

This gives Moderna an early sign that its treatment may help people with hard-to-treat multiple myeloma. The lack of serious treatment-related harms also supports continued testing. Still, only 12 patients had received it, so the findings may not hold in a larger group.